Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Molecular carcinogenesis"
DOI: 10.1002/mc.23357
Abstract: TP53 is the most frequently mutated gene in head and neck squamous cell carcinoma (HNSCC). Patients with HPV-negative TP53 mutant HNSCC have the worst prognosis, necessitating additional agents for treatment. Since mutant p53 causes sustained activation… read more here.
Keywords: autophagy; rad001; negative muttp53; cell ... See more keywords
A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.4
Abstract: 4Background: There is a need for effective treatments in the second- or further line setting in advanced gastric cancer, especially for new agents. In the current trial we evaluated paclitaxel with RAD001 (everolimus) in patients… read more here.
Keywords: fluoropyrimidine platinum; containing regimen; rad001; platinum containing ... See more keywords
Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells
Sign Up to like & getrecommendations! Published in 2018 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s160557
Abstract: Aim The mammalian target of rapamycin (mTOR) pathway is a critical target for cancer treatment and the mTOR inhibitor everolimus (RAD001) has been approved for treatment of renal cell carcinoma (RCC). However, the limited efficacy… read more here.
Keywords: cell; rad001; activation; induced autophagy ... See more keywords